
DW71177
CAS No. 2241311-72-6
DW71177( —— )
Catalog No. M37566 CAS No. 2241311-72-6
DW71177 is a bd1-selective and potent BET inhibitor with potent anti-leukemic activity for the study of leukemia.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 296 | Get Quote |
![]() ![]() |
5MG | 459 | Get Quote |
![]() ![]() |
10MG | 657 | Get Quote |
![]() ![]() |
25MG | 994 | Get Quote |
![]() ![]() |
50MG | 1371 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameDW71177
-
NoteResearch use only, not for human use.
-
Brief DescriptionDW71177 is a bd1-selective and potent BET inhibitor with potent anti-leukemic activity for the study of leukemia.
-
DescriptionDW71177 is a novel [1,2,4]triazolo[4,3-a] quinoxaline-based potent and BD1-Selective BET inhibitor, and can be used for study of acute myeloid leukemia.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorEpigenetic Reader Domain
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2241311-72-6
-
Formula Weight384.48
-
Molecular FormulaC20H28N6O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(NCCCCNC1=NC=2C=C(OC)C=CC2N3C1=NN=C3C)CC(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ali I, et al. DW71177: A novel [1,2,4]triazolo[4,3-a]quinoxaline-based potent and BD1-Selective BET inhibitor for the treatment of acute myeloid leukemia. Eur J Med Chem. Published online December 16, 2023.?
molnova catalog



related products
-
CPI-203
CPI-203 is a potent BET bromodomain inhibitor with IC50 of 37 nM for BRD4.
-
653-47 hydrochloride
653-47 hydrochloride is a potentiator, significantly potentiates the cAMP-response element binding protein (CREB) inhibitory activity of 666-15.?
-
GSK620
GSK620 is a pan-BD2 inhibitor, which shows an anti-inflammatory phenotype in human whole blood with excellent broad selectivity, developability, and in vivo oral pharmacokinetics.